行情

DMPI

DMPI

DelMar Pharma
NASDAQ

实时行情|Nasdaq Last Sale

0.6502
-0.0615
-8.64%
盘前: 0.6520 +0.0018 +0.28% 07:51 09/17 EDT
开盘
0.7150
昨收
0.7117
最高
0.7200
最低
0.6422
成交量
9,500
成交额
--
52周最高
8.50
52周最低
0.5520
市值
740.48万
市盈率(TTM)
-0.2046
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

DMPI 新闻

  • 美交通部宣布首批自动驾驶研究补助金去向 三州入围
  • TechWeb.3小时前
  • 亚马逊被曝“做手脚”推销其高利润率产品
  • 澎湃新闻.3小时前
  • 美联储内部严重分歧或令未来政策前景更扑朔迷离
  • 汇通网.3小时前
  • 沙特准备动用家底 但“最后一道防线”可能面临失守
  • 汇通网.3小时前

更多

所属板块

控股公司
-0.04%
金融
-0.29%

热门股票

名称
价格
涨跌幅

DMPI 简况

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
展开

Webull提供DelMar Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。